readthroughSign in
Nov 13, 2026Clinical readout

Rezolute says Phase 3 upLIFT study hits primary endpoint in tumor hyperinsulinism

Preliminary data from a November 5 analysis show 13 of 16 patients met the responder criterion, with full topline results expected by mid-December 2026.

Rezolute, Inc. (Nasdaq: RZLT) announced on November 13, 2026 that its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism (HI) has achieved its primary efficacy endpoint, based on preliminary results from a November 5th data evaluation of the ongoing open-label study.1

The study's primary efficacy endpoint is the proportion of patients able to achieve at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency for underlying hypoglycemia.1 To reach statistical significance, the lower bound of the 95% confidence interval for percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants.1

As of the data cut, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose, while three participants remain in the pivotal period, including two who have not yet met the responder criterion.1 One participant discontinued the study early, entered home hospice care, and died one week later due to cancer progression; this participant has been classified as a non-responder for purposes of the primary endpoint.1

The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas).1 The company said ersodetug has been well-tolerated to date in the pivotal and extension phases of the study, with no drug-related safety findings attributed to ersodetug.1

Under the trial protocol, eligible participants requiring continuous IV glucose receive ersodetug 9 mg/kg per week for 8 weeks as an add-on to standard of care, after which all participants may receive ersodetug at a reduced dosing frequency in long-term extension.1

Rezolute said results for the completed study, including statistical analysis of the primary endpoint, are expected by mid-December 2026.1 CEO Nevan Charles Elam said the company believes it is well positioned to advance both congenital HI and tumor HI into the approval process next year and looks forward to discussions with FDA in the first quarter of 2027.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.